Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JD Health International Inc.
京东健康股份有限公司
(A company incorporated in the Cayman Islands with limited liability)
(Stock Codes: 6618 (HKD counter) and 86618 (RMB counter))

VOLUNTARY ANNOUNCEMENT ON-MARKET PURCHASES FOR THE POST-IPO SHARE AWARD SCHEME

This announcement is made by JD Health International Inc. (the "**Company**" or "**JD Health**", and together with its subsidiaries and consolidated affiliated entities, the "**Group**") on a voluntary basis.

Reference is made to the post-IPO share award scheme of the Company adopted on November 23, 2020 (the "**Scheme**"). Pursuant to the Scheme, the Company has established a trust (the "**Trust**") and appointed a professional trustee (the "**Trustee**") for the purposes of administering this Scheme.

The board of directors of the Company (the "**Board**") announces that, on November 18, 2026, the Trustee purchased a total of 10,053,350 shares of the Company (the "**Shares**") on the open market for the purpose of satisfying the grant of awards under the Scheme. Details of the purchases by the Trustee are as follows:

Purchase date:	November 18, 2026
Total number of Shares purchased:	10,053,350
Percentage of the Shares purchased to the total number of Shares in issue as of the date of this announcement:	Approximately 0.32%
Average consideration per Share:	Approximately HK$34.80
Total consideration of Shares purchased:	Approximately HK$349,825,672

The Shares purchased will form part of the assets of the Trust and will be held by the Trustee for the benefit of the eligible participants of the Scheme in accordance with the Scheme and the trust arrangements. Subject to market conditions and applicable regulatory requirements, the Company may instruct the Trustee to make further purchases of Shares on the open market from time to time for the Scheme.

The Board is of the view that the on-market purchase of Shares in accordance with the Scheme demonstrates the Company's confidence in its business outlook and prospects, and also serves as part of the Company's strategy to attract and retain talent and align the interests of the eligible participants of the Scheme with the interests of the Company for the sustainable long-term growth of the Group.

By order of the Board
JD Health International Inc.
Mr. Dong Cao
Executive Director

Hong Kong, November 19, 2026

As of the date of this announcement, the Board comprises Mr. Dong Cao as the executive Director, Mr. Richard Qiangdong Liu as non-executive Director, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen, Mr. Ying Wu and Professor George Lau as independent non-executive Directors.